Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Lean Technologies secures US$67.5M in Series B funding led by General Catalyst to expand its open banking infrastructure ...

Mineralys Therapeutics, Inc. ( (MLYS) ) has released its Q3 earnings. Here is a breakdown of the information Mineralys Therapeutics, Inc.

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Cybersecurity, an area pivotal for companies implementing new technologies ... Creating an online account for a business that ...

Mavorixafor was generally well tolerated as a monotherapy and in combination with G-CSF, with no drug-related serious adverse ...

How was ODU pivotal in you becoming an entrepreneur? ODU was pivotal. I started my first company Dash Analytics while I was ...

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...